Skip to main content
Premium Trial:

Request an Annual Quote

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization granted on Friday emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports. China approved the vaccine from the state-owned Sinopharm in January.

The emergency approval adds a new vaccine to COVAX's arsenal, the Washington Post adds. COVAX was established earlier in the pandemic to enable global and equitable sharing of COVID-19 vaccines and made its first shipment in February. However, the effort has also been hindered by wealthier countries procuring vaccines directly from developers, rather than through the initiative, and by concerns over a lack of transparency.

"This expands the list of COVID-19 vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine,” WHO director general Tedros Adhanom Ghebreyesus said during a Friday press briefing, according to the Post.

The Guardian adds that the WHO recommends the vaccine for adults 18 years and older in a two-dose regimen, though notes the analysis included few adults over the age of 65.

According to the Post, the emergency approval also bolsters the international stature of Sinopharm, as this is the first such approval given by the WHO to a Chinese-made vaccine.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.